Cerevance is focused on the development of precision treatments for central nervous system disorders, including chronic neurodegenerative conditions such as Alzheimer’s disease, Parkinson’s disease, frontotemporal dementia and amyotrophic lateral sclerosis (ALS).

Ensoma is developing one-time in vivo treatments that precisely engineer any cell of the hematopoietic system to cure diseases from within.

Nido Biosciences develops first-in-class small molecule therapeutics for the treatment of neurological diseases. We are taking a precision medicine approach against novel genetically validated targets and are advancing multiple programs.

ReCode Therapeutics is a clinical-stage genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics. ReCode’s selective organ targeting (SORT) lipid nanoparticle (LNP) platform is a next-generation, genetic medicines technology that enables precise delivery to target organs and cells beyond the liver.

SURGE Therapeutics (The Intraoperative Immunotherapy Company™) seeks to dramatically improve cancer patient survival by disrupting how, when, and where cancer immunotherapy is deployed.